methicillin-resistant Staphylococcus aureus
methicillin-resistant Staphylococcus aureus
Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is a drug-resistant bacterial pathogen within the species Staphylococcus aureus that is defined by resistance to methicillin and, by extension, many other beta-lactam antibiotics. Clinically, MRSA is an important cause of skin and soft tissue infection, wound infection, pneumonia, bloodstream infection, and invasive disease, and it is frequently discussed in the context of multidrug-resistant bacterial infections. Its resistance profile makes it a major target for antimicrobial development, diagnostic innovation, and wound-healing research.
In recent biomedical studies, MRSA is often used as a model organism for evaluating antibacterial platforms that combine photothermal therapy, photodynamic therapy, nanozyme activity, copper-based antibacterial mechanisms, CRISPR-based detection, and wound dressings. These studies commonly compare MRSA with other pathogens such as Pseudomonas aeruginosa and Escherichia coli, or place it in the context of mixed infections, infected wounds, pneumonia, and diagnostic assays. The recurring focus is on overcoming the limitations of conventional antibiotics such as vancomycin and improving local or targeted eradication of resistant bacteria.
Role in Recent Research
Recent publications have used MRSA as a model target for both therapeutic development and diagnostic innovation. Several studies focused on infected wound healing. A hyaluronic acid-based hydrogel loaded with berberine hydrochloride was reported to promote MRSA-infected wound healing and showed strong anti-MRSA biofilm activity, with 59.7% biofilm eradication in the optimized formulation at 156 µg/mL. In a related wound-healing context, a programmable metal-nucleic acid biomineralized hydrogel containing Cu-Tsi@Gel was described as disrupting bacterial membranes, killing MRSA and other bacteria, and promoting angiogenesis through VEGF/CD31 upregulation. Another wound-focused study on MoS2/CoSe2 hybrid nanocomposites reported remarkable antibacterial action, achieving 99.71% bactericidal efficiency against MRSA in bacterially infected diabetic wounds.
Nanomaterial-based antimicrobial strategies were also prominent. Slippery, nitric oxide-releasing surfaces incorporating copper nanoparticles were reported to eradicate MRSA with greater than 99.8% reduction in bacterial cell viability, alongside strong activity against E. coli. Similarly, quantum dot-phage nanoarchitectonics were developed for targeted synergistic therapy of MRSA wound infections, addressing the challenge of chronic wound infections that are often refractory to conventional therapies because of drug resistance and biofilm formation. A metal-phenolic network nanoparticle system was also investigated for bacterial keratitis, where MRSA keratitis was highlighted as especially difficult to manage because of escalating antibiotic resistance and severe inflammation.
Other studies explored small molecules and natural products. A multivalent glycopolymer design was reported to unlock antimicrobial activity of 2-deoxyglucose, with poly2DG showing broad-spectrum inhibition including against MDR MRSA, Pseudomonas aeruginosa, and Acinetobacter baumannii, with MIC50 values as low as 0.2 μg/mL. An integrated virtual screening, machine learning, and molecular dynamics study identified novel phytochemical FabI inhibitors against MRSA, reflecting continued interest in essential bacterial pathways as drug targets. In a separate medicinal chemistry effort, tyrcinnamine derivatives were synthesized and evaluated as bactericides, and compound 14 showed significant bactericidal activity against Staphylococcus aureus and MRSA. Another benzimidazole derivative, BI-10, was described as a broad-spectrum antimicrobial targeting the bacterial membrane, with activity against priority pathogens.
Natural-product and ethnopharmacology-oriented work also included MRSA. An in-vitro and in-silico study of the Mayan medicinal plant Krugiodendron ferreum examined anti-staphylococcal effects and explicitly included MRSA as a clinically important resistant strain. A nanoemulsion of Palo Santo (Bursera graveolens) essential oil showed enhanced antimicrobial activity against Staphylococcus aureus, including MRSA isolates, while exhibiting pathogen-dependent selectivity relative to bovine mastitis-associated strains such as C. bovis and S. uberis. Another study on avocado oil and an anti-staphylococcal extract also contributed to this broader natural-product research theme.
Diagnostic innovation was represented by an RPA combined with CRISPR/Cas12a for rapid and ultrasensitive dual-gene detection of MRSA. This work emphasized the need for rapid and reliable diagnostic methods in response to the increasing burden of MRSA infections. In clinical pharmacology, a case report described high-dose vancomycin therapy for a MRSA abscess in a patient with type 2 diabetes and augmented renal clearance, and the report discussed dosing strategy implications as well as vancomycin-associated acute kidney injury. Together, these studies show that MRSA remains a central target for antimicrobial discovery, biofilm disruption, wound therapy, and rapid molecular detection.